ArticleVirchows Archiv : an international journal of pathology2026
Nodal metastases in papillary thyroid microcarcinoma: prevalence and risk factors in 311 patients.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic Factors and Recurrence in Papillary Thyroid Microcarcinoma.Medicina (Kaunas, Lithuania) · 2026Article
- Case Report: Concomitant BRAF V600E and PIK3CA H1047R mutations in a micro-papillary thyroid carcinoma with extensive nodal metastasis.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Papillary thyroid microcarcinoma (PTMC) is generally considered low risk due to its favourable prognosis; however, in some cases, it presents aggressive features such as lymph node metastasis and extrathyroidal extension (ETE). The aim of this study was to investigate the pathological factors that influence prognosis in PTMC with the purpose of refining risk stratification based on our cohort of 311 cases. We performed a retrospective analysis based on anonymous data from 311 PTMC samples (tumours ≤ 1.0 cm in size) collected between 2016 and 2024. We examined several variables, including gender, histological subtype, tumour size, ETE, lymph node metastasis, and thyroiditis. The evaluations followed the eighth edition of the American Joint Committee on Cancer (AJCC) staging system. We used Pearson's chi-square test for univariate analysis and binary logistic regression for multivariate analysis. A p-value less than 0.05 was considered statistically significant. In our cohort, 45 patients (14.5%) had lymph node metastases. Male sex (OR = 3.3132; 95% CI = 1.5554-7.0574; p = 0.002), age < 45 years (OR = 2.4974; 95% CI = 1.2228-5.1006; p = 0.012), multicentricity (OR = 2.9351; 95% CI = 1.4314-6.0182; p = 0.003) and vascular invasion (OR = 3.5184; 95% CI = 1.3044-9.4905; p = 0.013) are found to be independent risk factors for lymph node metastases. The tall cell histological subtype (OR = 3.897; 95% CI = 1.6649-9.122; p = 0.002) emerged as an independent predictor of ETE. Although PTMC is commonly considered an indolent neoplasm, some cases may present aggressive features that require careful prognostic evaluation. The identification of independent risk factors may improve clinical decision-making and therapeutic strategies for patients with PTMC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.